177 related articles for article (PubMed ID: 35115949)
1. A FAK Inhibitor Boosts Anti-PD1 Immunotherapy in a Hepatocellular Carcinoma Mouse Model.
Wei Y; Wang Y; Liu N; Qi R; Xu Y; Li K; Feng Y; Shi B
Front Pharmacol; 2021; 12():820446. PubMed ID: 35115949
[TBL] [Abstract][Full Text] [Related]
2. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
3. Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy.
Sun G; Liu H; Zhao J; Zhang J; Huang T; Sun G; Zhao S; Zhang Z; Cao H; Rong D; Kong X; Ji Q; Liu L; Wang X; Tang W; Xia Y
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600662
[TBL] [Abstract][Full Text] [Related]
4. Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma.
Ou DL; Lin YY; Hsu CL; Lin YY; Chen CW; Yu JS; Miaw SC; Hsu PN; Cheng AL; Hsu C
Liver Cancer; 2019 May; 8(3):155-171. PubMed ID: 31192153
[TBL] [Abstract][Full Text] [Related]
5. Combination of AFP vaccine and immune checkpoint inhibitors slows hepatocellular carcinoma progression in preclinical models.
Lu X; Deng S; Xu J; Green BL; Zhang H; Cui G; Zhou Y; Zhang Y; Xu H; Zhang F; Mao R; Zhong S; Cramer T; Evert M; Calvisi DF; He Y; Liu C; Chen X
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37040183
[TBL] [Abstract][Full Text] [Related]
6. Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody.
Morita M; Nishida N; Sakai K; Aoki T; Chishina H; Takita M; Ida H; Hagiwara S; Minami Y; Ueshima K; Nishio K; Kobayashi Y; Kakimi K; Kudo M
Liver Cancer; 2021 Jul; 10(4):380-393. PubMed ID: 34414125
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma.
Shigeta K; Matsui A; Kikuchi H; Klein S; Mamessier E; Chen IX; Aoki S; Kitahara S; Inoue K; Shigeta A; Hato T; Ramjiawan RR; Staiculescu D; Zopf D; Fiebig L; Hobbs GS; Quaas A; Dima S; Popescu I; Huang P; Munn LL; Cobbold M; Goyal L; Zhu AX; Jain RK; Duda DG
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33234602
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
9. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.
Wei CY; Zhu MX; Zhang PF; Huang XY; Wan JK; Yao XZ; Hu ZT; Chai XQ; Peng R; Yang X; Gao C; Gao J; Wang SW; Zheng YM; Tang Z; Gao Q; Zhou J; Fan JB; Ke AW; Fan J
J Hepatol; 2022 Jul; 77(1):163-176. PubMed ID: 35219791
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma.
Sun G; Miao G; Li Z; Zheng W; Zhou C; Sun G; Cao H; Li Z; Tang W
J Oncol; 2022; 2022():6988923. PubMed ID: 35466317
[TBL] [Abstract][Full Text] [Related]
11. TOX promotes the exhaustion of antitumor CD8
Wang X; He Q; Shen H; Xia A; Tian W; Yu W; Sun B
J Hepatol; 2019 Oct; 71(4):731-741. PubMed ID: 31173813
[TBL] [Abstract][Full Text] [Related]
12. Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma.
Kong X; Zheng Z; Song G; Zhang Z; Liu H; Kang J; Sun G; Sun G; Huang T; Li X; Rong D; Wang K; Tang W; Xia Y
Front Immunol; 2022; 13():876048. PubMed ID: 35812439
[TBL] [Abstract][Full Text] [Related]
13. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
14. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
[TBL] [Abstract][Full Text] [Related]
15. Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway.
Guangshun S; Guoqiang S; Xin C; Xiangyi K; Wubin Z; Zhitao L; Zhiying Z; Hongyong C; Chengyu L; Yongxiang X; Weiwei T
J Oncol; 2022; 2022():4598573. PubMed ID: 35237322
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers.
Myojin Y; McCallen JD; Ma C; Bauer KC; Ruf B; Benmebarek MR; Green BL; Wabitsch S; McVey JC; Fu C; Xie C; Greten TF
JHEP Rep; 2024 Jan; 6(1):100959. PubMed ID: 38192537
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics reveals ascorbic acid inhibits ferroptosis in hepatocytes and boosts the effectiveness of anti-PD1 immunotherapy in hepatocellular carcinoma.
Sun G; Liu C; Lu Z; Zhang J; Cao H; Huang T; Dai M; Liu H; Feng T; Tang W; Xia Y
Cancer Cell Int; 2024 May; 24(1):192. PubMed ID: 38822322
[TBL] [Abstract][Full Text] [Related]
18. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
[TBL] [Abstract][Full Text] [Related]
19. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).
Wan Y; Ge K; Zhou W; Lu J; Jia C; Zhu H
Biol Chem; 2021 May; 402(6):729-737. PubMed ID: 33583159
[TBL] [Abstract][Full Text] [Related]
20. Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma.
Pinato DJ; Kaneko T; D'Alessio A; Forner A; Fessas P; Minguez B; Giannini EG; Grillo F; Díaz A; Mauri FA; Fulgenzi CAM; Dalla Pria A; Goldin RD; Pieri G; Toniutto P; Avellini C; Plaz Torres MC; Akarca AU; Marafioti T; Bhoori S; Miró JM; Bower M; Bräu N; Mazzaferro V
JHEP Rep; 2023 Jul; 5(7):100741. PubMed ID: 37274775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
